Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Idorsia Ltd.
Industry Sector: HealthTechnology
CEO: André C. Muller, MBA
Number Of Employees: N/A
Enterprise Value: $1,420,949,063
PE Ratio: -0.75
Exchange/Ticker 1: SIX:IDIA
Exchange/Ticker 2: N/A
Latest Market Cap: $266,174,892
BioCentury | Feb 19, 2025
Deals
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report
Plus: Antithrombotic comes back to Novartis via deal for Anthos, Newleos debuts with portfolio of Roche assets, and more
BioCentury | Feb 12, 2025
Management Tracks
New CEOs at Aro and Navigator
Plus: Arbuckle retiring from Vertex, and updates from Lb, Glox, Titan and more
BioCentury | Jan 13, 2025
Deals
Lilly catches Relay in PI3Ka race via Scorpion acquisition
A spinout will house precision oncology assets from Scorpion
BioCentury | Dec 3, 2024
Deals
The week in deals: Acadia taps Saniona for GABRA3 modulator, and more
Deals Report: Roche-Poseida, Novartis-PTC and Sarepta-Arrowhead forge large deals, as Idorsia keeps the lights on into 2025
BioCentury | Oct 25, 2024
Deals
James Sabry on industry-shaping changes in innovation and deal-making
Business development veteran talks to BioCentury as he transitions from Roche to BioMarin, entering the one biotech segment he’s not yet been in
BioCentury | Jul 13, 2024
Politics, Policy & Law
On track to squeeze FDA budget, Congress still makes detailed demands of agency
Report language includes boost for Idorsia, endorsement of accelerated approval and demand to suspend LDT rule
BioCentury | May 29, 2024
Deals
Deals Report: Three $1B+ takeouts highlight demand in immunology, renal
Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more
BioCentury | May 22, 2024
Management Tracks
Eden Wells to lead insights and decision science at Novartis
Plus: Nurix appoints Julia Gregory as chair, and updates from Valneva, Alto, Cour and Kronos
BioCentury | May 21, 2024
Management Tracks
Clozel looks to next chapter as Idorsia chair
CFO André Muller to succeed Clozel as CEO
BioCentury | Apr 30, 2024
Data Byte
EMA’s CHMP recommends Takeda VEGF therapy, Idorsia hypertension drug
April opinions also include earlier-line use of J&J’s Rybrevant and BMS’s Opdivo
Items per page:
1 - 10 of 76